JP7603578B2 - 多価抗体 - Google Patents

多価抗体 Download PDF

Info

Publication number
JP7603578B2
JP7603578B2 JP2021502692A JP2021502692A JP7603578B2 JP 7603578 B2 JP7603578 B2 JP 7603578B2 JP 2021502692 A JP2021502692 A JP 2021502692A JP 2021502692 A JP2021502692 A JP 2021502692A JP 7603578 B2 JP7603578 B2 JP 7603578B2
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
binding domain
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021502692A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519610A (ja
Inventor
コルネリス・アドリアーン・デ・クライフ
リンダ・ヨハンナ・アレイダ・ヘンドリクス
トン・ルグテンベルグ
ピーテル・フォッコ・ファン・ロー
Original Assignee
メルス ナムローゼ フェンノートシャップ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メルス ナムローゼ フェンノートシャップ filed Critical メルス ナムローゼ フェンノートシャップ
Publication of JP2021519610A publication Critical patent/JP2021519610A/ja
Priority to JP2024136804A priority Critical patent/JP2024161509A/ja
Application granted granted Critical
Publication of JP7603578B2 publication Critical patent/JP7603578B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021502692A 2018-03-30 2019-03-29 多価抗体 Active JP7603578B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024136804A JP2024161509A (ja) 2018-03-30 2024-08-16 多価抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650467P 2018-03-30 2018-03-30
US62/650,467 2018-03-30
PCT/NL2019/050199 WO2019190327A2 (en) 2018-03-30 2019-03-29 Multivalent antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024136804A Division JP2024161509A (ja) 2018-03-30 2024-08-16 多価抗体

Publications (2)

Publication Number Publication Date
JP2021519610A JP2021519610A (ja) 2021-08-12
JP7603578B2 true JP7603578B2 (ja) 2024-12-20

Family

ID=66349617

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021502692A Active JP7603578B2 (ja) 2018-03-30 2019-03-29 多価抗体
JP2024136804A Pending JP2024161509A (ja) 2018-03-30 2024-08-16 多価抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024136804A Pending JP2024161509A (ja) 2018-03-30 2024-08-16 多価抗体

Country Status (18)

Country Link
US (3) US11952424B2 (https=)
EP (1) EP3774885A2 (https=)
JP (2) JP7603578B2 (https=)
KR (1) KR20200139189A (https=)
CN (1) CN111936514A (https=)
AR (1) AR115320A1 (https=)
AU (2) AU2019243665B2 (https=)
BR (1) BR112020019795A2 (https=)
CA (1) CA3094318A1 (https=)
EA (1) EA202091871A1 (https=)
IL (1) IL277672A (https=)
MA (1) MA52212A (https=)
MX (1) MX2020010267A (https=)
NZ (1) NZ767923A (https=)
PH (1) PH12020551504A1 (https=)
SG (1) SG11202009036YA (https=)
TW (1) TW202003569A (https=)
WO (1) WO2019190327A2 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
CN113227132A (zh) 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
US20220380440A1 (en) 2018-12-31 2022-12-01 Merus N.V. Truncated multivalent multimers
TW202546002A (zh) 2019-03-29 2025-12-01 荷蘭商美勒斯公司 Cd3結合分子
CN114605546A (zh) * 2019-03-29 2022-06-10 美勒斯公司 Cd3结合分子
US20210054049A1 (en) 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
CN116199780A (zh) 2019-12-24 2023-06-02 美勒斯公司 TGF-β-RII结合蛋白质
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法
JP7784039B2 (ja) * 2020-03-31 2025-12-11 公立大学法人大阪 多重特異性抗体及びその製造方法
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
EP4149627A4 (en) * 2020-05-14 2024-05-29 The General Hospital Corporation POLYPEPTIDE AGONISTS OF THE TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY
WO2021226984A1 (zh) 2020-05-15 2021-11-18 三生国健药业（上海）股份有限公司 一种抗pd-1和pd-l1的四价双特异性抗体
MX2022014208A (es) 2020-05-21 2022-12-07 Merus Nv Metodos y medios para la produccion de moleculas tipo ig.
CA3196729A1 (en) * 2020-11-11 2022-05-19 Tural AKSEL Affinity reagents having enhanced binding and detection characteristics
CN115536749A (zh) * 2021-06-29 2022-12-30 三生国健药业（上海）股份有限公司 三特异性抗体、其制备方法和用途
CN119110809A (zh) 2022-02-23 2024-12-10 Xencor股份有限公司 抗CD28 x抗PSMA抗体
US20240117030A1 (en) * 2022-03-03 2024-04-11 Pfizer Inc. Multispecific antibodies and uses thereof
JP2025512391A (ja) * 2022-04-13 2025-04-17 ゼンコア インコーポレイテッド Ｐｄ－ｌ１、ｐｄ－ｌ２及び／またはｃｄ２８と結合する抗体
TW202432587A (zh) 2022-12-27 2024-08-16 荷蘭商美勒斯公司 產生雙特異性蛋白之方法
EP4642800A1 (en) * 2022-12-30 2025-11-05 Merus N.V. Promiscuous cd3 binding molecules
CN116813744B (zh) * 2023-02-23 2024-02-23 暨南大学 一种识别mage-a3抗原短肽的t细胞受体及其应用
US20240327515A1 (en) * 2023-03-31 2024-10-03 Ibio, Inc. Anti-cd3 antibodies
WO2025221674A1 (en) * 2024-04-15 2025-10-23 Eli Lilly And Company Baffr x cd3 bispecific antibodies and methods of use
WO2025230409A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2025230410A1 (en) 2024-04-30 2025-11-06 Merus N.V. Multispecific antibody-drug conjugates
WO2026013015A1 (en) * 2024-07-09 2026-01-15 Merus N.V. Multispecific binding moieties comprising calr and cd3 binding domains
WO2026018064A1 (en) 2024-07-16 2026-01-22 Merus N.V. Multispecific multi-drug antibody-drug conjugates

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523205A (ja) 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
WO2011086091A1 (en) 2010-01-12 2011-07-21 Ucb Pharma S.A. Multivalent antibodies
JP2015532278A (ja) 2012-09-27 2015-11-09 メルス・ベー・フェー Ｔ細胞エンゲージャーとしての二重特異性ＩｇＧ抗体

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
JP4213224B2 (ja) 1997-05-02 2009-01-21 ジェネンテック，インコーポレーテッド ヘテロマルチマー及び共通成分を有する多重特異性抗体の製造方法
CN101289511A (zh) * 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
CA2410551A1 (en) 2000-06-30 2002-01-10 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) Heterodimeric fusion proteins
NZ537277A (en) 2002-07-18 2008-04-30 Crucell Holland Bv Recombinant production of mixtures of antibodies
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL3456190T3 (pl) 2008-06-27 2022-06-06 Merus N.V. Wytwarzające przeciwciała transgeniczne zwierzę z gatunku myszy
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
CA2762837C (en) 2009-05-20 2021-08-03 Novimmune S.A. Synthetic polypeptide libraries and methods for generating naturally diversified polypeptide variants
TW201100543A (en) * 2009-05-27 2011-01-01 Hoffmann La Roche Tri-or tetraspecific antibodies
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
ES2542744T3 (es) 2009-12-17 2015-08-11 Novimmune Sa Bibliotecas de polipéptidos sintéticos y métodos para generar variantes polipeptídicas diversificadas de forma natural
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
EP2748197A2 (en) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
SI2838917T1 (sl) * 2012-04-20 2019-11-29 Merus Nv Postopki in sredstva za produkcijo heterodimernih IG-podobnih molekul
CN113967253A (zh) 2012-05-15 2022-01-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
HK1204557A1 (en) 2012-05-31 2015-11-27 Sorrento Therapeutics, Inc. Antigen binding proteins that bind pd-l1
US20150203591A1 (en) * 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JP6636803B2 (ja) 2013-02-05 2020-01-29 エンクマフ エスアーエールエル Ｂｃｍａに対する抗体の選択のための方法
CA2896359A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
BR112016015140A2 (pt) * 2013-12-30 2018-01-23 Epimab Biotherapeutics Inc. imunoglobulina com fabs in-tandem e usos das mesmas
IL301147A (en) 2014-02-28 2023-05-01 Merus Nv An antibody that binds to ErbB-2 and ErbB-3
EP3786186A1 (en) 2014-02-28 2021-03-03 Merus N.V. Antibodies that bind egfr and erbb3
EP3152235B1 (en) 2014-05-29 2021-08-25 MacroGenics, Inc. Tri-specific binding molecules and methods of use thereof
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP3204416A1 (en) 2014-10-09 2017-08-16 EngMab AG Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
WO2016105450A2 (en) * 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法
SI3115376T1 (sl) * 2015-07-10 2018-12-31 Merus N.V. Humana protitelesa, ki vežejo CD3
US10683369B2 (en) 2015-08-03 2020-06-16 Engmab Sàrl Monoclonal antibodies against BCMA
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CA3002957A1 (en) * 2015-10-23 2017-04-27 Koninklijke Nederlandse Akademie Van Wetenschappen Binding molecules that inhibit cancer growth
CN109476741B (zh) 2016-03-25 2023-02-24 拜奥穆尼克斯制药 与cd38和pd-l1结合的分子
JP2019516362A (ja) * 2016-04-27 2019-06-20 ファイザー・インク 抗ｉｌ−３３抗体、その組成物、方法および使用
CN109563166B (zh) 2016-04-28 2022-12-20 拜奥穆尼克斯制药 靶向egfr和her2的双特异性抗体
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
BR112019005895A2 (pt) * 2016-09-23 2019-06-11 Merus N.V. moléculas de ligação que modulam uma atividade biológica expressa por uma célula
KR20240000650A (ko) 2016-10-19 2024-01-02 인벤라 인코포레이티드 항체 구조물
EP4295918A3 (en) 2016-11-02 2024-03-20 Bristol-Myers Squibb Company Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
AU2018246873B2 (en) * 2017-03-31 2021-05-06 Merus B.V. ErbB-2 and ErbB3 binding bispecific antibodies for use in the treatment f cells that have an NRG1 fusion gene
EA202090005A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Антитела, модулирующие биологическую активность, проявляемую клеткой
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
EP3649155A1 (en) * 2017-07-06 2020-05-13 Merus N.V. Bispecific anti pd1-anti tim3 antibodies
CN118580366A (zh) * 2017-08-09 2024-09-03 美勒斯公司 结合EGFR和cMET的抗体
CN111432838A (zh) * 2017-12-01 2020-07-17 美勒斯公司 使用双特异性抗体和il-15进行联合治疗
MX2020010267A (es) 2018-03-30 2020-11-06 Merus Nv Anticuerpo multivalente.
CN113227132A (zh) * 2018-12-31 2021-08-06 美勒斯公司 混合的结合域
US20210054049A1 (en) * 2019-05-09 2021-02-25 Merus N.V. Variant domains for multimerizing proteins and separation thereof
PH12022551291A1 (en) * 2019-11-26 2023-11-20 Novartis Ag Chimeric antigen receptors binding bcma and cd19 and uses thereof
CN116407626A (zh) * 2020-01-29 2023-07-11 美勒斯公司 用于调节免疫细胞衔接效应的手段和方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523205A (ja) 2000-07-25 2004-08-05 イムノメディクス， インコーポレイテッド 多価標的結合タンパク質
WO2011086091A1 (en) 2010-01-12 2011-07-21 Ucb Pharma S.A. Multivalent antibodies
JP2015532278A (ja) 2012-09-27 2015-11-09 メルス・ベー・フェー Ｔ細胞エンゲージャーとしての二重特異性ＩｇＧ抗体

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Digiammarino E L. et al.，Ligand association rates to the inner-variable-domain of a dual-variable-domain immunoglobulin are significantly impacted by linker design，Mabs，2011年，Vol. 3(5)，pp. 487-494
Grummt M. et al.，Importance of a flexible hinge near the motor domain in kinesin-driven motility，EMBO J，1998年，Vol. 17(19)，pp. 5536-5542
Klement M. et al.，Effect of linker flexibility and length on the functionality of a cytotoxic engineered antibody fragment，J Biotechnol，2015年，Vol. 199，pp. 90-97
Kontermann R E，Dual targeting strategies with bispecific antibodies，MAbs，2012年，Vol. 4(2)，pp. 182-197
Meehan R R. et al.，HP1 binding to native chromatin in vitro is determined by the hinge region and not by the chromodomain，EMBO J，2003年，Vol. 22(12)，pp. 3164-3174
Zhao L. et al.，A JAK2 interdomain linker relays Epo receptor engagement signals to kinase activation，J Biol Chem，2009年，Vol. 284(39)，pp. 26988-26998

Also Published As

Publication number Publication date
JP2021519610A (ja) 2021-08-12
WO2019190327A8 (en) 2021-06-17
EA202091871A1 (ru) 2021-06-22
MX2020010267A (es) 2020-11-06
US20190352401A1 (en) 2019-11-21
AR115320A1 (es) 2020-12-23
IL277672A (en) 2020-11-30
AU2019243665A1 (en) 2020-10-08
CN111936514A (zh) 2020-11-13
JP2024161509A (ja) 2024-11-19
US20240352127A1 (en) 2024-10-24
AU2019243665B2 (en) 2023-06-01
NZ767923A (en) 2024-11-29
TW202003569A (zh) 2020-01-16
SG11202009036YA (en) 2020-10-29
MA52212A (fr) 2021-02-17
WO2019190327A3 (en) 2019-11-14
AU2023222983A1 (en) 2023-09-21
BR112020019795A2 (pt) 2021-01-05
EP3774885A2 (en) 2021-02-17
KR20200139189A (ko) 2020-12-11
US20240360217A1 (en) 2024-10-31
PH12020551504A1 (en) 2021-09-13
WO2019190327A2 (en) 2019-10-03
CA3094318A1 (en) 2019-10-03
US11952424B2 (en) 2024-04-09

Similar Documents

Publication Publication Date Title
JP7603578B2 (ja) 多価抗体
AU2019274656B2 (en) Anti-CD3 antibodies and uses thereof
TW202227491A (zh) 抗ｒｏｒ１抗體及相關雙特異性結合蛋白
US20150183877A1 (en) Multi-Specific IgG-(Fab)2 Constructs Containing T-Cell Receptor Constant Domains
HK1217958A1 (zh) 四价双特异性抗体
AU2026202570A1 (en) Antibodies
US20250136688A1 (en) Stabilized cd3 antigen binding agents and methods of use thereof
JP6579097B2 (ja) 新規ヒトｔｌｒ２及びヒトｔｌｒ４に結合する二重特異的抗体
WO2024184812A1 (en) Anti-cldn6 antibodies and methods of use
JP2023547329A (ja) Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
US20250075002A1 (en) MUC1 and CD16A Antibodies and Methods of Use
JP2026507191A (ja) Ｍｕｃ１抗体及び使用方法
KR20250156803A (ko) 항-cd3 다중특이적 항체 및 사용 방법
KR20250158060A (ko) 항-cldn6 및 항-cd3 다중특이적 항체 및 사용 방법
EP4676962A1 (en) Anti-cldn6 antibodies and methods of use
TW202436353A (zh) 抗ｃｌｄｎ６與抗ｃｄ３多重特異性抗體以及使用方法
TW202436345A (zh) 抗ｃｄ３多特異性抗體及使用方法
KR20230004739A (ko) 인간화 항-인간 cd89 항체 및 이의 용도
HK40096583A (zh) 能够结合ror2的抗体以及结合ror2和cd3的双特异性抗体
EA045935B1 (ru) Антитела к cd3 и их применение

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211126

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230821

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240221

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240430

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240816

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240826

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241210

R150 Certificate of patent or registration of utility model

Ref document number: 7603578

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313111

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350